Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (NASDAQ: HBIO) is a life science tools company that develops, manufactures and sells technologies, products and services used in research, drug and therapy discovery, bio‑production and preclinical testing. News about Harvard Bioscience often centers on how its laboratory instruments and platforms support life science applications for academic institutions, government laboratories, pharmaceutical companies, biotechnology firms and contract research organizations.
Investors and researchers following HBIO news will find regular updates on quarterly financial results, including revenues, gross margins, net income or loss, adjusted EBITDA and cash flows from operations, as reported in the company’s earnings press releases. These announcements are typically accompanied by guidance ranges for upcoming quarters and commentary on demand trends, backlog and operational discipline.
Harvard Bioscience news also covers capital structure and financing developments. In 2025, the company reported amendments to its existing credit agreement, discussions with lenders, and the execution of a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, along with associated warrants and board nomination rights. These items appear in both press releases and Form 8‑K filings and are relevant to readers tracking the company’s liquidity, debt profile and going‑concern considerations.
Another theme in HBIO coverage is corporate governance and leadership changes. The company has announced a CEO succession plan, the appointment of new independent directors, and the designation of a lead independent director. Additional news items describe board appointments linked to financing arrangements and changes in audit committee composition. Operational news has included expanded distribution agreements for laboratory equipment with a major scientific supplier and references to technologies such as pumps, spectrophotometers, BTX electroporation systems and Mesh MEA organoid platforms.
For readers interested in HBIO, this news stream provides context on the company’s financial performance, governance, listing status on Nasdaq, and its role in supplying tools for life science research and preclinical testing. Regular updates can help observers understand how Harvard Bioscience is managing its business and capital structure while serving global life science customers.
Harvard Bioscience (Nasdaq: HBIO) has scheduled its third quarter 2024 financial results announcement for November 7, 2024, before market opening. The company will host a conference call at 8:00 AM ET to discuss the results. Participants wanting to ask questions must pre-register to receive dial-in information and a PIN. An audio-only webcast option is also available through the company's investor website, where the earnings release and related presentation materials will be accessible.
Harvard Bioscience (Nasdaq: HBIO) will showcase its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting in Chicago. Key highlights include:
1. Mesh MEA™ microelectrode array system: Captures electrophysiology signals from inside organoids in real-time, providing new insights into neural dynamics and brain disorders.
2. SoHo™ implantable telemetry platform: Allows data collection from multiple small animal models in a shared housing environment, integrated with the Ponemah™ data management platform.
3. VivaMARS™ activity monitoring system: Offers real-time behavioral testing for neurological research and neuropharmacology studies, reducing operating expenses and test cycle times.
The company will also display its new Heka™ patch clamp amplifiers and other products supporting in vitro and in vivo neuroscience research. Harvard Bioscience will exhibit at booth #925 at the McCormick Place Convention Center from October 6-9, 2024.
Harvard Bioscience (Nasdaq: HBIO) is showcasing its latest product innovations at the Safety Pharmacology Society Annual Meeting from September 22-25, 2024, in San Diego. The company is presenting several key solutions:
1. DSI Ponemah Data Management Platform: An integrated preclinical solution for managing and analyzing data from various studies.
2. SoHo Implantable Real-Time Telemetry: A system for small animal models, enabling longer duration studies and increased testing throughput.
3. VivaMARS Activity Monitoring System: A platform for real-time, high-throughput behavioral testing in neuropharmacology safety and toxicology studies.
4. MCS Mesh MEA Organoid Platform: Designed for organoid applications in research, safety pharmacology, and toxicology, allowing real-time electrophysiology measurements inside living organoids.
Harvard Bioscience (Nasdaq: HBIO) has announced its participation in the Sidoti Small Cap Virtual Conference on September 18th, 2024. Jim Green, Chairman and CEO, and Jennifer Cote, CFO, will represent the company with a presentation scheduled for 9:15 am ET.
The presentation will be webcast live through the investor relations section of Harvard Bioscience's website. A replay will be available shortly after the presentation concludes. Interested parties can schedule one-on-one meetings through the conference organizers.
This event provides an opportunity for investors to gain insights into Harvard Bioscience's operations and future prospects directly from its top executives.
Harvard Bioscience (NASDAQ: HBIO) reported challenging Q2 2024 financial results. Revenues decreased to $23.1 million from $28.8 million in Q2 2023. The company experienced a net loss of $2.9 million, compared to a $1.0 million loss in the same period last year. Gross margin slightly declined to 57.2% from 58.0%.
Adjusted EBITDA fell to $1.3 million from $3.9 million in Q2 2023. The company implemented cost-saving measures expected to yield $4 million in annualized savings. Due to delayed market recovery, Harvard Bioscience reduced its 2024 revenue outlook to $97-102 million, with an expected gross margin of 59-60% and adjusted EBITDA margin in high single digits.
Harvard Bioscience (Nasdaq: HBIO) has announced its schedule for the second quarter 2024 earnings conference call, set for August 8, 2024, at 10:00 AM ET. The company will release its financial results for the quarter ended June 30, 2024, before the market opens on the same day. Interested participants can register for the call to ask questions, while an audio-only webcast option is also available. Financial information, including the earnings release and a related slide presentation, will be accessible on the Investor Relations section of Harvard Bioscience's website.
Harvard Bioscience (Nasdaq: HBIO) will present and host one-on-one meetings at the 14th Annual East Coast IDEAS Conference in New York City on June 12, 2024. Chairman and CEO Jim Green, along with CFO Jennifer Cote, will address investors from 2:45-3:20 PM ET at the Jay Conference Center – Bryant Park. The presentation will be webcast live and accessible via the company's investor relations website, with a replay available shortly afterward. To schedule individual meetings, investors should contact the conference team at Three Part Advisors.
Harvard Bioscience announced that CEO Jim Green and CFO Jennifer Cote will present at the Jefferies Global Healthcare Conference on June 5, 2024.
The event will be held at the Marriott Marquis, New York City, from 2:00 to 2:25 PM Eastern Time.
The presentation will be webcast live via the Harvard Bioscience investor relations website, with a replay available afterwards.
Additionally, the company will host one-on-one meetings with investors during the conference.
For scheduling these meetings, investors can contact healthcareconference@jefferies.com.
Harvard Bioscience announced that its CEO, Jim Green, and CFO, Jennifer Cote, will participate in the Benchmark Healthcare House Call Virtual Conference on May 22, 2024. The event will feature a live fireside chat from 9:00-9:40 am ET and one-on-one meetings with investors. Interested parties can register for the presentation or schedule meetings via the Benchmark website.
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced its first quarter 2024 financial results, reporting revenues of $24.5 million, a gross margin of 60.3%, and adjusted EBITDA of $1.6 million. Despite challenges in certain markets, the company remains focused on efficiency and growth, with a cost reduction initiative in place. The net loss for the quarter was $(4.7) million, with a decrease in revenues compared to the prior year. The company expects flat revenues for 2024, with second-half growth and a gross margin of 60%. Harvard Bioscience will be hosting a conference call to discuss the results.